Two medicines, side by side
Posaconazole vs voriconazole
Posaconazole and voriconazole are both labeled for fungal infections. Drugs@FDA records approvals of posaconazole since 2006 and of voriconazole since 2002. Pharmacies paid $2.03 per posaconazole DR 100 mg tablet and $1.88 per voriconazole 200 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Posaconazole, “Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ].”; Voriconazole, “Voriconazole is an antifungal drug [see Microbiology (12.4) ].”
Check it at the source: the posaconazole FDA label on DailyMed (effective August 3, 2026); the voriconazole FDA label on DailyMed (effective February 26, 2026).
Highlights of the posaconazole record
Posaconazole (Noxafil) · label of August 3, 2026
Used for
From the label: indicationsPosaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies […]
On the market
- Earliest approval on file
- September 15, 2006
- Generic labelers
- 27 labelers
- Pharmacy cost
- $2.03 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 2
Highlights of the voriconazole record
Voriconazole (Vfend) · label of February 26, 2026
Used for
From the label: indicationsVFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or […]
On the market
- Earliest approval on file
- May 24, 2002
- Generic labelers
- 31 labelers
- Pharmacy cost
- $1.88 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 4
Source: FDA drug labels via openFDA (Posaconazole label of August 3, 2026, Voriconazole label of February 26, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do posaconazole and voriconazole differ on the record?
How each works, in its label's words: Posaconazole, “Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ].”; Voriconazole, “Voriconazole is an antifungal drug [see Microbiology (12.4) ].”
Both are in FDA's class azole antifungals.
Generics: posaconazole since 2019; voriconazole since 2010 (Drugs@FDA).
| Posaconazole | Voriconazole | |
|---|---|---|
| Labeled for | Fungal infections | Fungal infections |
| Pharmacologic class | Azole Antifungal | Azole Antifungal |
| How it works (label) | Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ]. | Voriconazole is an antifungal drug [see Microbiology (12.4) ]. |
| Half-life (label) | Posaconazole delayed-release tablet is eliminated with a mean half-life (t ½ ) ranging between 26 to 31 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | September 15, 2006 | May 24, 2002 |
| First generic approved | August 21, 2019 | April 22, 2010 |
| Generic labelers (NDC) | 27 labelers | 31 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $2.03 per tablet (Posaconazole DR 100 mg tablet) | $1.88 per tablet (Voriconazole 200 mg tablet) |
| 12-month price change | -46% | -2% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
| Recalls recorded | 2 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 16,154 | 30,201 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to posaconazole
- every medicine labeled for the same conditions